216 related articles for article (PubMed ID: 36509078)
1. Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms.
DeZern AE; Greenberg PL
J Natl Compr Canc Netw; 2022 Dec; 20(12):1280-1283. PubMed ID: 36509078
[TBL] [Abstract][Full Text] [Related]
2. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age.
Xie Z; Chen EC; Stahl M; Zeidan AM
Blood Rev; 2023 May; 59():101033. PubMed ID: 36357283
[TBL] [Abstract][Full Text] [Related]
3. [Molecular international prognostic scoring system for myelodysplastic syndromes].
Nagata Y
Rinsho Ketsueki; 2023; 64(5):355-368. PubMed ID: 37271526
[TBL] [Abstract][Full Text] [Related]
4. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.
Lee WH; Tsai MT; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Liu MC; Yang YT; Chen JC; Tang JL; Sun HI; Chuang YK; Lin LI; Chou WC; Lin CC; Hou HA; Tien HF
Blood Cancer J; 2023 Aug; 13(1):120. PubMed ID: 37558665
[TBL] [Abstract][Full Text] [Related]
5. Molecular Drivers of Myelodysplastic Neoplasms (MDS)-Classification and Prognostic Relevance.
Hoff FW; Madanat YF
Cells; 2023 Feb; 12(4):. PubMed ID: 36831294
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Molecular International Prognostic Scoring System (M-IPSS) and Revised International Prognostic Scoring System (R-IPSS) in Thai patients with myelodysplastic neoplasms.
Polprasert C; Niparuck P; Rattanathammethee T; Kobbuaklee S; Lanamtieng T; Rojnuckarin P
Hematology; 2022 Dec; 27(1):1301-1304. PubMed ID: 36519260
[TBL] [Abstract][Full Text] [Related]
8. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
9. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M; Bewersdorf JP; Xie Z; Porta MGD; Komrokji R; Xu ML; Abdel-Wahab O; Taylor J; Steensma DP; Starczynowski DT; Sekeres MA; Sanz G; Sallman DA; Roboz GJ; Platzbecker U; Patnaik MM; Padron E; Odenike O; Nimer SD; Nazha A; Majeti R; Loghavi S; Little RF; List AF; Kim TK; Hourigan CS; Hasserjian RP; Halene S; Griffiths EA; Gore SD; Greenberg P; Figueroa ME; Fenaux P; Efficace F; DeZern AE; Daver NG; Churpek JE; Carraway HE; Buckstein R; Brunner AM; Boultwood J; Borate U; Bejar R; Bennett JM; Wei AH; Santini V; Savona MR; Zeidan AM
Blood Rev; 2023 Nov; 62():101128. PubMed ID: 37704469
[TBL] [Abstract][Full Text] [Related]
10. Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study.
Condorelli A; Frigeni M; Quaresmini G; Salmoiraghi S; Pavoni C; Grassi A; Raviglione M; Civini A; Putelli A; Lussana F; Finazzi MC; Algarotti A; Micò MC; Spinelli O; Rambaldi A
Leuk Res; 2024 Jul; 142():107529. PubMed ID: 38820666
[TBL] [Abstract][Full Text] [Related]
11. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta E; Robin M; Bersanelli M; Travaglino E; Meggendorfer M; Zhao LP; Caballero Berrocal JC; Sala C; Maggioni G; Bernardi M; Di Grazia C; Vago L; Rivoli G; Borin L; D'Amico S; Tentori CA; Ubezio M; Campagna A; Russo A; Mannina D; Lanino L; Chiusolo P; Giaccone L; Voso MT; Riva M; Oliva EN; Zampini M; Riva E; Nibourel O; Bicchieri M; Bolli N; Rambaldi A; Passamonti F; Savevski V; Santoro A; Germing U; Kordasti S; Santini V; Diez-Campelo M; Sanz G; Sole F; Kern W; Platzbecker U; Ades L; Fenaux P; Haferlach T; Castellani G; Della Porta MG
J Clin Oncol; 2023 May; 41(15):2827-2842. PubMed ID: 36930857
[TBL] [Abstract][Full Text] [Related]
12. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
Maggioni G; Della Porta MG
Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
[TBL] [Abstract][Full Text] [Related]
13. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
[TBL] [Abstract][Full Text] [Related]
14. When to use which molecular prognostic scoring system in the management of patients with MDS?
Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
[TBL] [Abstract][Full Text] [Related]
15. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
Khanna V; Lu R; Kumar J; Molina A; Stehr H; Spiteri E; Spinner M; Silva O; Fernandez-Pol S; Tan B; Greenberg PL
Leuk Res; 2024 Jan; 136():107433. PubMed ID: 38154193
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndromes, version 2.2015.
Greenberg PL; Stone RM; Bejar R; Bennett JM; Bloomfield CD; Borate U; De Castro CM; Deeg HJ; DeZern AE; Fathi AT; Frankfurt O; Gaensler K; Garcia-Manero G; Griffiths EA; Head D; Klimek V; Komrokji R; Kujawski LA; Maness LJ; O'Donnell MR; Pollyea DA; Scott B; Shami PJ; Stein BL; Westervelt P; Wheeler B; Shead DA; Smith C;
J Natl Compr Canc Netw; 2015 Mar; 13(3):261-72. PubMed ID: 25736003
[TBL] [Abstract][Full Text] [Related]
18. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
Greenberg PL; Stone RM; Al-Kali A; Bennett JM; Borate U; Brunner AM; Chai-Ho W; Curtin P; de Castro CM; Deeg HJ; DeZern AE; Dinner S; Foucar C; Gaensler K; Garcia-Manero G; Griffiths EA; Head D; Jonas BA; Keel S; Madanat Y; Maness LJ; Mangan J; McCurdy S; McMahon C; Patel B; Reddy VV; Sallman DA; Shallis R; Shami PJ; Thota S; Varshavsky-Yanovsky AN; Westervelt P; Hollinger E; Shead DA; Hochstetler C
J Natl Compr Canc Netw; 2022 Feb; 20(2):106-117. PubMed ID: 35130502
[TBL] [Abstract][Full Text] [Related]
19. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
[TBL] [Abstract][Full Text] [Related]
20. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
Lucero J; Al-Harbi S; Yee KWL
Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
